Wagner Hans-Joachim, Fischer Lars, Jabs Wolfram J, Holbe Meike, Pethig Klaus, Bucsky Peter
Department of Pediatrics, Medical University of Lübeck.
Transplantation. 2002 Sep 15;74(5):656-64. doi: 10.1097/00007890-200209150-00012.
Posttransplant lymphoproliferative disease (PTLD) is a significant cause of morbidity and mortality in transplant recipients and is caused by iatrogenic suppression of T cell function. Elevations in the Epstein-Barr viral (EBV) load in plasma (>1000 EBV copies/100 microL plasma) or peripheral blood mononuclear cells (PBMC) (>5000 EBV copies/microg PBMC DNA) as determined by real-time quantitative polymerase chain reaction (RQ-PCR) have been shown to be sensitive indicators for the development of PTLD in patients.
The diagnostic value of frequent monitoring of EB viral load in peripheral blood from 46 patients after heart transplantation was investigated compared with 21 healthy controls in a prospective longitudinal study. EB viral load was detected in PBMC and plasma using real-time quantitative (RQ)- polymerase chain reaction (PCR)-based assays and compared with serological parameters of EBV infection or with the occurrence of CMV reactivations.
EB viral load was significantly increased in PBMC and in plasma from transplanted patients compared with healthy controls. Regarding levels and fluctuations of EB viral load in PBMC, patients were grouped in three distinct categories with high, intermediate, or low EB viral load. Although in one patient without PTLD, the EB viral load exceeded the threshold value for PTLD of 5000 EBV copies/microg PBMC DNA, all patients had an EB viral load in plasma of less than 1000 EBV copies/100 microL plasma. No correlation was found between the level of EB viral load and serological parameters of EBV reactivations in patients or in healthy control individuals. EBV and cytomegalovirus reactivations occurred independently in the majority of patients.
EB viral load measurements in plasma and PBMC of patients using RQ-PCR are superior to serology and are a powerful tool for monitoring transplanted patients.
移植后淋巴细胞增生性疾病(PTLD)是移植受者发病和死亡的重要原因,由T细胞功能的医源性抑制引起。通过实时定量聚合酶链反应(RQ-PCR)测定,血浆中爱泼斯坦-巴尔病毒(EBV)载量升高(>1000 EBV拷贝/100微升血浆)或外周血单个核细胞(PBMC)中EBV载量升高(>5000 EBV拷贝/微克PBMC DNA)已被证明是患者发生PTLD的敏感指标。
在一项前瞻性纵向研究中,对46例心脏移植术后患者外周血中EB病毒载量的频繁监测与21例健康对照者的诊断价值进行了比较。使用基于实时定量(RQ)-聚合酶链反应(PCR)的检测方法检测PBMC和血浆中的EB病毒载量,并与EBV感染的血清学参数或巨细胞病毒再激活的发生情况进行比较。
与健康对照相比,移植患者的PBMC和血浆中EB病毒载量显著增加。根据PBMC中EB病毒载量的水平和波动情况,患者被分为EB病毒载量高、中、低三个不同类别。虽然在1例无PTLD的患者中,EB病毒载量超过了PTLD的阈值5000 EBV拷贝/微克PBMC DNA,但所有患者血浆中的EB病毒载量均低于1000 EBV拷贝/100微升血浆。在患者或健康对照个体中,未发现EB病毒载量水平与EBV再激活的血清学参数之间存在相关性。在大多数患者中,EBV和巨细胞病毒再激活是独立发生的。
使用RQ-PCR测量患者血浆和PBMC中的EB病毒载量优于血清学检测,是监测移植患者的有力工具。